Berberine · BBR · Berberine Hydrochloride
Natural insulin sensitizer that compounds GLP-1 metabolic outcomes.
FDA
Approved
WADA
Not Listed
HALF-LIFE
~4–5 hours
ROUTE
Oral
SCHEDULE
3× daily with meals
In Plain English
Natural insulin sensitizer that compounds GLP-1 metabolic outcomes.
Status & Legality
NATTY?
No Test ExistsNo established test exists for this compound.
FDA
ApprovedFDA approved for human use.
WADA
Not ListedNot currently on WADA prohibited list.
COMPOUNDING
Rx AvailableAvailable at licensed pharmacies with prescription.
PRESCRIBED
By prescriptionPhysicians can prescribe this compound legally.
ROUTE
OralAdministration via oral.
Insulin sensitization
Blood glucose control
GLP-1 metabolic synergy
Lipid management
Berberine activates AMPK (the same pathway as metformin) and improves insulin receptor sensitivity. Multiple RCTs show it lowers HbA1c, fasting glucose, and LDL-C comparably to first-line medications. Combined with GLP-1 peptides, berberine provides a complementary mechanism — GLP-1 slows gastric emptying and reduces appetite while berberine improves peripheral insulin sensitivity, producing additive metabolic improvements.
GI upset, diarrhea, nausea — common initially, resolves in 2–4 weeks
Constipation in some users
Hypoglycemia risk with insulin or sulfonylureas
CYP450 inhibition — check drug interactions
Taking all at once instead of spreading 3× daily — the short half-life (~4 hours) requires split dosing for consistent blood levels and efficacy
Not warning about hypoglycemia risk when combining with insulin or sulfonylureas — the additive glucose-lowering effect is clinically significant
Starting at full dose immediately — GI side effects are common the first 2–4 weeks; begin at 500 mg once daily and titrate up
Metformin — additive AMPK effects; hypoglycemia risk when combined; monitor glucose and consider reducing metformin
Insulin and sulfonylureas — significant hypoglycemia risk; reduce doses when adding berberine
CYP450 substrates — berberine inhibits CYP2D6 and CYP3A4; check drug interactions for any CYP-metabolized medications
Berberine's glucose-lowering effect is comparable to metformin in multiple RCTs — this is not typical supplement-grade evidence. The CYP450 drug interactions are the most important safety consideration; check your full medication list. Combined with GLP-1 agonists, the additive metabolic improvement is real and meaningful, but so is the hypoglycemia risk.
Stats
Sources & Studies
Dong H. et al., Evid Based Complement Alternat Med, 2012